Efficacy and Safety of a Poly-L-Lactic Acid Filler for Temporal Augmentation: A Randomized, No-treatment Control, Evaluator-blinded, Multicenter Study
Aesthetic Surgery Journal · 18.05.2026 · 46 (6) · 652-662
DOI: 10.1093/asj/sjag013 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Aesthetic Surgery Journal, online erschienen am 04.02.2026. Verfasst von Guojing Chang und 7 weiteren Autor:innen. Hauptthemen laut MEDLINE: Dermal Fillers, Polyesters, Cosmetic Techniques, Skin Aging. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 48 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Hebei Shanyuan Technology Co., Ltd, Shi Jia Zhuang Shi, China.
Abstract (Originalsprache)
Background
Temple hollowing represents a prevalent aesthetic concern traditionally addressed with autologous fat grafting or hyaluronic acid fillers. Poly-L-lactic acid (PLLA) offers gradual, collagen-mediated volumization and is increasingly utilized for soft tissue augmentation. Nevertheless, to date, no approved study has evaluated its use for temporal augmentation.
Objectives
The aim of this study was to evaluate the efficacy and safety of a PLLA facial filler for the augmentation of temple hollowing.
Methods
This randomized, no-treatment control, evaluator-blinded, multicenter clinical trial enrolled 174 participants with moderate to severe temple hollowing, randomized 2:1 to the treatment or control group. The treatment group received 2 to 3 sessions of PLLA bilateral temporal injections with 12-month follow-up, and the control group received no treatment within 6 months after randomization. Efficacy was assessed with the Allergan Temple Hollowing Scale (ATHS), Global Aesthetic Improvement Scale (GAIS), 3-dimensional (3D) volume change of temples, and participant-reported satisfaction. Safety evaluations included adverse events (AEs), injection-site reactions, vital signs, and laboratory tests.
Results
At Month 6, 96.5% of participants in the treatment group achieved an at least 1-grade improvement on the ATHS, in contrast to 0% in the control group (P < .0001). Consistent and significant improvements were observed across all secondary endpoints, including ATHS efficacy rates assessed by both blinded evaluators and injection investigators at all follow-up visits up to 12 months, GAIS improvement rates, and temporal volume measured by 3D imaging. Aesthetic improvement and participant satisfaction were rated highly at all follow-up visits. PLLA was safe and well tolerated, with no therapy-related adverse events reported.
Conclusions
PLLA facial filler effectively improved temple hollowing and achieved aesthetic enhancement for up to 12 months, with an excellent safety profile. Level of Evidence: 1 (Therapeutic)For image description, please refer to the figure legend and surrounding text.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
Förderung
- Hebei Shanyuan Technology Co., Ltd
- Shi Jia Zhuang Shi, China
Zitieren
APA
Chang, G., Tan, Z., Ting, W., Bi, H., Wang, H., Zhang, A., Yu, N., & Long, X. (2026). Efficacy and Safety of a Poly-L-Lactic Acid Filler for Temporal Augmentation: A Randomized, No-treatment Control, Evaluator-blinded, Multicenter Study. Aesthetic Surgery Journal, 46(6), 652-662. https://doi.org/10.1093/asj/sjag013
Vancouver
Chang G, Tan Z, Ting W, Bi H, Wang H, Zhang A, et al. Efficacy and Safety of a Poly-L-Lactic Acid Filler for Temporal Augmentation: A Randomized, No-treatment Control, Evaluator-blinded, Multicenter Study. Aesthetic Surgery Journal. 2026;46(6):652-662. doi:10.1093/asj/sjag013
BibTeX
@article{Chang2026,
author = {Chang, Guojing and Tan, Zhaoqi and Ting, Wenyun and Bi, Hongsen and Wang, Hang and Zhang, Aijun and Yu, Nanze and Long, Xiao},
title = {Efficacy and Safety of a Poly-L-Lactic Acid Filler for Temporal Augmentation: A Randomized, No-treatment Control, Evaluator-blinded, Multicenter Study},
journal = {Aesthetic Surgery Journal},
year = {2026},
volume = {46},
number = {6},
pages = {652--662},
doi = {10.1093/asj/sjag013}
}
EUVIMED